Basic Information
| LncRNA/CircRNA Name | CASC2 |
| Synonyms | NA |
| Region | GRCh38_10:118046279-118210153 |
| Ensemble | ENSG00000177640 |
| Refseq | NR_026939 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Cisplatin (DDP) | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, Luciferase reporter assay etc |
| Sample | NSCLC tissues,cell lines(H226, H520, SK-MES-1, A549, H1975, H1299, BEAS-2B) |
| Expression Pattern | differential expressed |
| Function Description | Low CASC2 expression is more likely to present in patients with advanced TNM stage (IV), cisplatin-resistance, and poor overall survival. The expression of CASC2 sharply decreased in cisplatin-resistant NSCLC tissues and cell lines (H226/DDP and A549/DDP). CASC2 overexpression strongly inhibited proliferation, migration, and invasion of cisplatin-resistant NSCLC cells (H226/DDP and A549/DDP) in vitro and inhibited tumor growth in vivo. |
| Pubmed ID | 32271431 |
| Year | 2020 |
| Title | ELF1 Activated Long Non-Coding RNA CASC2 Inhibits Cisplatin Resistance of Non-Small Cell Lung Cancer via the miR-18a/IRF-2 Signaling Pathway |
External Links
| Links for CASC2 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |